WallStSmart

EchoStar Corporation (SATS)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

EchoStar Corporation generates 366% more annual revenue ($15.00B vs $3.22B). WST leads profitability with a 16.9% profit margin vs -96.6%. SATS appears more attractively valued with a PEG of 1.34. WST earns a higher WallStSmart Score of 67/100 (B-).

SATS

Avoid

34

out of 100

Grade: F

Growth: 2.0Profit: 3.0Value: 7.0Quality: 2.5
Piotroski: 3/9Altman Z: -0.08

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SATSUndervalued (+66.0%)

Margin of Safety

+66.0%

Fair Value

$323.23

Current Price

$127.15

$196.08 discount

UndervaluedFair: $323.23Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SATS0 strengths · Avg: 0/10

No standout strengths identified

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

SATS4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-111.3%2/10

ROE of -111.3% — below average capital efficiency

Revenue GrowthGrowth
-4.3%2/10

Revenue declined 4.3%

EPS GrowthGrowth
-85.6%2/10

Earnings declined 85.6%

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : SATS

PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : SATS

The primary concerns for SATS are Piotroski F-Score, Return on Equity, Revenue Growth. Debt-to-equity of 4.40 is elevated, increasing financial risk.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

SATS profiles as a turnaround stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.17 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 34/100), backed by strong 16.9% margins and 21.0% revenue growth. SATS offers better value entry with a 66.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EchoStar Corporation

COMMUNICATION SERVICES · TELECOM SERVICES · USA

EchoStar Corporation provides broadband satellite technologies and broadband Internet services. The company is headquartered in Englewood, Colorado.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?